The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaEmmy D.G. Fleuren, Yvonne M.H. Versleijen‐Jonkers|Oncotarget|2014Cited by 47
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507Emmy D.G. Fleuren, Winette T.A. van der Graaf|Clinical Cancer Research|2011Cited by 42
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma SubtypesEmmy D.G. Fleuren, Roger J. Daly|Cancer Research|2017Cited by 35
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma modelsEmmy D.G. Fleuren, Winette T.A. van der Graaf|International Journal of Cancer|2014Cited by 21